A PHASE III PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB(ANTI-PD-L1 ANTIBODY)AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY

Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2016
This article has no abstract
Epistemonikos ID: c987abfd3473b0da1dc2cc9abfe83df90dca772b
First added on: Apr 16, 2025